Aller au contenu principal
Profil bibliographique

Emily Frances Brown

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

14Publications signalées
224Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsCardiovascular and exercise physiologyHigh Altitude and HypoxiaPharmacological Effects and Toxicity Studies

Les publications récentes

Accès ouvert 2026 article OpenAlex

Somatic DICER1-mutated Sertoli–Leydig cell tumor in a postmenopausal woman: eight years of peritoneal relapse managed with cytoreductive surgery and HIPEC – a case report

Emily Frances Brown, Katrina Tang, Ruwanthi Wijayawardana, Vivek Arora et autres

Sertoli-Leydig cell tumors are rare ovarian sex cord-stromal tumors that usually arise in young women and are often hormonally active. Intraperitoneal dissemination and relapse are uncommon, and recurrence patterns in postmenopausal women are poorly characterized. This report describes a 55-year-old postmenopausal woman …

au (code pays fourni par la source)

0 citations Case Reports in Women s Health
Accès ouvert 2025 article OpenAlex

Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancer

Emily Frances Brown, Ilaria Colombo, Ainhoa Madariaga, Lawrence Kasherman

Ovarian cancer remains the most lethal gynecologic malignancy, with immune evasion a major driver of therapeutic resistance and disease progression. Among novel targets, the immune checkpoint molecules B7-H3 and B7-H4 have been recognized for their potent immunosuppressive roles and selective overexpression in …

au, ch, es (code pays fourni par la source)

3 citations Frontiers in Immunology
Accès ouvert 2025 article OpenAlex

Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07–523LS in Newborn Infants Exposed to HIV-1

Coleen K. Cunningham, Elizabeth J. McFarland, Petronella Muresan, Edmund V. Capparelli et autres

BACKGROUND: Vertical HIV-1 transmission despite antiretroviral therapy may be mitigated by the use of long-acting, broadly neutralizing, monoclonal antibodies (bNAb) such as VRC07-523LS. The present study was designed to determine the safety and pharmacokinetics of VRC07-523LS. METHODS: VRC07-523LS, 80 mg/dose, was administered …

us, Afrique du Sud, Zimbabwe (code pays fourni par la source)

12 citations Journal of the Pediatric Infectious Diseases Society
2021 article OpenAlex

Azole Antifungals: An Update

Emily Frances Brown

Imidazoles and triazoles are two types of azole antifungals that have the same mechanism of action. Imidazoles have a two-nitrogen azole ring and are mostly used topically; triazoles, which have three nitrogens in the azole ring, have largely replaced them for systemic …

0 citations Organic chemistry : an Indian journal
Accès ouvert 2020 article OpenAlex

Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa

Lynda Stranix‐Chibanda, Peter L. Anderson, Deborah Kacanek, Sybil Hosek et autres

BACKGROUND: Intracellular tenofovir diphosphate (TFV-DP) concentration in dried blood spots (DBSs) is used to monitor cumulative pre-exposure prophylaxis (PrEP) adherence. We evaluated TFV-DP in DBSs following daily oral PrEP (emtricitabine 200 mg/tenofovir diphosphate 300 mg) among pregnant and postpartum adolescent girls and …

Zimbabwe, us, Malawi, Ouganda, Afrique du Sud (code pays fourni par la source)

66 citations Clinical Infectious Diseases
Accès ouvert 2020 article OpenAlex

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis

Paul A Krogstad, Pearl M. Samson, Edward P. Acosta, Jack Moye et autres

Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to …

us, Afrique du Sud (code pays fourni par la source)

9 citations Journal of the Pediatric Infectious Diseases Society
Accès ouvert 2017 article OpenAlex

The role of hydrophobic silane coating on Si stamps in nanoimprint lithography

Alborz Amirsadeghi, Lance Austin Brumfield, Junseo Choi, Emily Frances Brown et autres

Hydrophobic silane coatings have been successfully applied to the surface of Si stamps to improve demolding in nanoimprint lithography (NIL). However, the role of the silane coating has only been studied either indirectly, by measuring adhesion or friction coefficients for Si and …

us, kr (code pays fourni par la source)

14 citations Journal of Applied Physics
Accès ouvert 2015 article OpenAlex

An Adverse Drug Reaction to Trimethoprim-Sulfamethoxazole Revealing Primary HIV: A Case Report and Literature Review

Charles D. Meyer, Nicole Behm, Emily Frances Brown, Nathanial K. Copeland et autres

Adverse drug reactions (ADRs) to antibiotics complicate the management of any infection, particularly opportunistic infections in advanced HIV as some ADRs are potentiated by HIV. Trimethoprim-sulfamethoxazole (TMP-SMX) causes ADRs in 40-80% of HIV infected individuals, compared to 3-5% in the general population. …

us (code pays fourni par la source)

7 citations Case Reports in Infectious Diseases
1991 article OpenAlex

Safety Profile of Lacidipine

C.A. Endersby, Emily Frances Brown, Michael Sidney Perelman

The clinical safety of the new dihydropyridine calcium antagonist lacidipine was assessed in 14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated with an alternative antihypertensive agent. The type and incidence of adverse events seen with lacidipine were characteristic …

fr (code pays fourni par la source)

8 citations Journal of Cardiovascular Pharmacology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.